BERLIN—Barley beta-glucan reduces serum lipid levels, according to research presented in April at the First International Congress on Pre-Diabetes and Metabolic Syndrome.
In the six-week study, 76 men and 79 women with hypercholesterolemia, aged
25 to 73, completed a four-week lowfat diet prior to baseline. At the beginning of the trial, test subjects were randomly allocated to one of four treatment groups or a control group and assayed for blood lipids and other cardiovascular disease (CVD) biomarkers. During the course of the study, test groups were administered 3 g and 5 g doses of low molecular weight (LMW) or high molecular weight (HMW) barley beta-glucan (from Cargill) twice daily, in cereal and juice.
Posttreatment assessment of blood lipids and other CVD biomarkers revealed improvements in low-density lipoprotein (LDL) cholesterol, triglycerides, markers of glycemic control
(glycosylated hemoglobin, HOMA model) and a key marker of inflammation
(hs-CRP).
The researchers concluded both doses of LMW and HMW barley beta-glucan improved blood lipids over a six-week treatment period.
